United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - eftrenonacog alfa - powder and solvent for solution for injection - 1000unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - eftrenonacog alfa - powder and solvent for solution for injection - 2000unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - eftrenonacog alfa - powder and solvent for solution for injection - 3000unit

European Union - English - EMA (European Medicines Agency)

glaxosmithkline trading services limited - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - elebrato ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

European Union - English - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - naloxone hydrochloride dihydrate - opioid-related disorders - all other therapeutic products - nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings.nyxoid is indicated in adults and adolescents aged 14 years and over.nyxoid is not a substitute for emergency medical care.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline trading services - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - trelegy ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

European Union - English - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - meropenem trihydrate, vaborbactam - urinary tract infections; bacteremia; bacterial infections; respiratory tract infections; pneumonia; pneumonia, ventilator-associated - antibacterials for systemic use, - vaborem is indicated for the treatment of the following infections in adults:complicated urinary tract infection (cuti), including pyelonephritiscomplicated intra-abdominal infection (ciai)hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap).treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.vaborem is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options.consideration should be given to official guidance on the appropriate use of antibacterial agents.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline trading services limited - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - temybric ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptom control and prevention of exacerbations see section 5.1).

European Union - English - myHealthbox

merck sharp & dohme limited - lamivudine, raltegravir potassium - film-coated tablets - 150 mg of lamivudine and 300 mg of raltegravir - hiv infections - antivirals for systemic use - indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the insti (integrase strand transfer inhibitor) and nrti (nucleoside reverse transcriptase inhibitor) classes

European Union - English - myHealthbox

alcon laboratories (uk) ltd. - nepafenac - eye drops, suspension - 3mg/1 ml - ophthalmologic surgical procedures, postoperative pain - ophthalmologicals, anti-inflammatory agents, non-steroids - prevention and treatment of postoperative pain and inflammation associated with cataract surgery